Search

Search Constraints

You searched for: Author/Creator Gordon, Kenneth

Search Results

3. FRI0435 INFLUENCE OF BASELINE DEMOGRAPHICS AND DISEASE CHARACTERISTICS ON EFFICACY OF AN ORAL, SELECTIVE TYK2 INHIBITOR, BMS-986165, IN PATIENTS WITH PLAQUE PSORIASIS IN A PHASE 2 TRIAL. (June 2019)

5. A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, double‐blinded trial. (1st June 2020)

6. Sustained and continuously improved efficacy of tildrakizumab in patients with moderate-to-severe plaque psoriasis. (16th November 2020)

7. Validation of the Psoriasis Symptom Inventory (PSI), a patient-reported outcome measure to assess psoriasis symptom severity. (October 2013)